<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03576027</url>
  </required_header>
  <id_info>
    <org_study_id>Dembinski2018</org_study_id>
    <nct_id>NCT03576027</nct_id>
  </id_info>
  <brief_title>Hyperbaric Oxygen Therapy in Children With Inflammatory Bowel Diseases</brief_title>
  <official_title>Evaluation of the Effectiveness of Hyperbaric Oxygen Therapy in the Treatment of Inflammatory Bowel Disease in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Military Institute of Medicine, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study assesses the effectiveness of hyperbaric oxygen therapy in the treatment of
      inflammatory bowel disease in children.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the ulcerative colitis activity</measure>
    <time_frame>40 days</time_frame>
    <description>Change in the disease activity based on the Paediatric Ulcerative Colitis Activity Index (PUCAI) for patients with ulcerative colitis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of the Crohn's disease activity</measure>
    <time_frame>40 days</time_frame>
    <description>Change in the disease activity based on the Pediatric Crohn's Disease Activity Index (PCDAI) for patients with Crohn's disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>40 days</time_frame>
    <description>Number of participants with treatment-related adverse events and the the severity of these events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of proinflammatory cytokines</measure>
    <time_frame>40 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintaining remission of the ulcerative colitis</measure>
    <time_frame>1 year</time_frame>
    <description>Duration of the clinical remission time (if achieved) assessed according to the Paediatric Ulcerative Colitis Activity Index (PUCAI) for patients with ulcerative colitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintaining remission of the Crohn's disease</measure>
    <time_frame>1 year</time_frame>
    <description>Duration of the clinical remission time (if achieved) assessed according to the Pediatric Crohn's Disease Activity Index (PCDAI) for patients with Crohn's disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Children, Only</condition>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperbaric Oxygen Therapy</intervention_name>
    <description>Hyperbaric Oxygen Therapy</description>
    <arm_group_label>Hyperbaric oxygen therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of Crohn's disease or ulcerative colitis according to the criteria from
             Porto - based on the clinical condition as well as imaging and endoscopic examinations
             with histopathological assessment;

          -  failure to achieve the remission despite the use of standard treatment in accordance
             with international guidelines;

          -  written consent of the patient's legal guardians and the patient himself if he/she
             turns 16 years of age.

        Exclusion Criteria:

          -  intolerance of enclosed spaces;

          -  contraindications for hyperbaric therapy: otolaryngological (otitis media, sinusitis);
             cardiac (clinically significant defects or arrhythmias); pneumological (clinically
             significant defects)

          -  exacerbation of inflammatory bowel disease during the therapy;

          -  contraindications for hyperbaric therapy in a patient's caregiver in a situation,
             where the patient requires his/hers presence inside the hyperbaric chamber during the
             session.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lukasz Dembinski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Warsaw, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lukasz Dembinski, MD</last_name>
    <phone>+48 22 317 9449</phone>
    <email>lukaszdembinski@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02-091</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukasz Dembinski, MD</last_name>
      <phone>+48 22 317 9449</phone>
      <email>lukaszdembinski@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 3, 2018</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Warsaw</investigator_affiliation>
    <investigator_full_name>Lukasz Dembinski</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

